InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.23
(
0.00%
)
US TECH 100
19,403.60
(
0.01%
)
Dow Jones
38,778.10
(
0.00%
)
Brent Oil
83.97
(
0.08%
)
Bitcoin
64,877.76
(
-2.42%
)
Post# of 252235
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119861
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 226594

Thursday, 11/21/2019 5:41:30 PM

Thursday, November 21, 2019 5:41:30 PM

Post# of 252235
REPH spins off BXRX—retaining only the CDMO business:

https://www.globenewswire.com/news-release/2019/11/21/1951117/0/en/Recro-Completes-Separation-of-Baudax-Bio-and-Becomes-a-Dedicated-Contract-Development-and-Manufacturing-Organization.html

Recro Pharma…today announced that it has completed the spin out of its Acute Care segment, Baudax Bio. Baudax Bio common stock will begin “regular way” trading on Friday, November 22, 2019, under the symbol “BXRX” on the Nasdaq Capital Market.

Each REPH share will receive 0.4 shares of BXRX as a non-taxable distribution.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up